Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 9/20 | 0.44 |
| ▸ | DLK1 | P80370 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CRACR2A | Q9BSW2 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25646934 | 0.94 | MAP3K12 (0.41) | MAP3K12DLK1TSHRCRACR2AKDM4E | |
| SCHEMBL14555383 | 0.94 | MAP3K12 (0.43) | MAP3K12DLK1TSHRCRACR2AKDM4E | |
| SCHEMBL15723617 | 0.89 | MAP3K12 (0.41) | MAP3K12DLK1TSHRCRACR2A | |
| SCHEMBL25230154 | 0.88 | MAP3K12 (0.40) | MAP3K12DLK1TSHRCRACR2APOLB | |
| SCHEMBL25221503 | 0.84 | MAP3K12 (0.38) | MAP3K12DLK1TSHRCRACR2AKDM4E | |
| SCHEMBL30409305 | 0.83 | MAP3K12 (0.36) | MAP3K12DLK1CRACR2A | |
| SCHEMBL25225550 | 0.83 | MAP3K12 (0.36) | MAP3K12DLK1CRACR2A | |
| SCHEMBL15723662 | 0.83 | MAP3K12 (0.40) | MAP3K12DLK1TSHR | |
| SCHEMBL25227346 | 0.81 | MAP3K12 (0.35) | MAP3K12DLK1CRACR2A | |
| SCHEMBL25270744 | 0.81 | MAP3K12 (0.35) | MAP3K12DLK1CRACR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067629-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-29 | — | — | US | disclosed |
| EP-3870576-B1 | BEZOPYRAZOLE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11753399-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20210395262-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-12-23 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10836746-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10668051-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2020-06-02 | — | — | US | disclosed |
| US-20190345136-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190248791-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS SA (CH) | 2019-08-15 | — | — | US | disclosed |
| US-9944631-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-17 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170313690-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | RHIZEN PHARMACEUTICALS AG (CH) | 2017-11-02 | — | — | US | disclosed |
| US-9758514-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2017-09-12 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170114060-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-27 | — | — | US | disclosed |
| US-8377970-B2 | Modulators of calcium release-activated calcium channel | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-19 | — | — | US | disclosed |
| US-20110112058-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | US | disclosed |
| WO-2011042797-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL | ICOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668051-B2 | Modulators of calcium release-activated calcium channel | ORAI1, CACNB2, CACNB1 | MAP3K12 3048/4885DLK1 865/4885TSHR 3901/4885 |
| US-20170313690-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL | ORAI1, CACNB2, CACNA1E | MAP3K12 2595/4885DLK1 857/4885TSHR 3599/4885 |
| US-20110112058-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | MAP3K12 2505/4885DLK1 941/4885TSHR 3949/4885 |
| US-20240067629-A1 | THERAPEUTIC COMPOUNDS | NPC1, CCR5, FURIN | MAP3K12 2161/4885DLK1 4337/4885TSHR 4855/4885 |
| US-20190248791-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | MAP3K12 2505/4885DLK1 941/4885TSHR 3949/4885 |
| US-10836746-B2 | Therapeutic compounds | NPC1, CCR5, FURIN | MAP3K12 2161/4885DLK1 4337/4885TSHR 4855/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | MAP3K12 1616/4885DLK1 4834/4885TSHR 4824/4885 |
| US-20170114060-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | ZC3HAV1, MAVS, EIF2AK2 | MAP3K12 3385/4885DLK1 4070/4885TSHR 4476/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | MAP3K12 1616/4885DLK1 4834/4885TSHR 4824/4885 |
| US-20190345136-A1 | THERAPEUTIC COMPOUNDS | NPC1, CCR5, FURIN | MAP3K12 2161/4885DLK1 4337/4885TSHR 4855/4885 |
| US-11753399-B2 | Therapeutic compounds | NPC1, CCR5, FURIN | MAP3K12 2161/4885DLK1 4337/4885TSHR 4855/4885 |
| US-20210395262-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, REV1, POLR2E | MAP3K12 2803/4885DLK1 4597/4885TSHR 4821/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | MAP3K12 1616/4885DLK1 4834/4885TSHR 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.